Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:00:31.758Z.
Calculation as of: 2026-10-06T21:00:31.758Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6f641a2bf51a69a6e8cdb13afe7e76557325a462d28890c99da58f5868e3b8e6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$1.89B
EV/EBIT Ratio
251.96x
TTM Avg
240.22x
3Y Avg
240.22x
5Y Avg
240.22x
Market Cap
$1.92B
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. (AGIO) | $1.89B | N/A | N/A | N/A | N/A |
| Zymeworks Inc. (ZYME)vs › | $1.89B | N/A | 2.37x | 2.37x | 2.37x |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 251.96x | 240.22x | 240.22x | 240.22x |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.87B | N/A | N/A | N/A | N/A |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.92B | N/A | N/A | N/A | N/A |
| Novavax, Inc. (NVAX)vs › | $1.86B | N/A | 3.63x | 3.63x | 3.63x |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $1.94B | N/A | N/A | N/A | N/A |
| Immunome, Inc. (IMNM)vs › | $1.85B | N/A | N/A | N/A | N/A |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.84B | N/A | N/A | N/A | N/A |
| AxoGen, Inc. (AXGN)vs › | $1.95B | N/A | 408.25x | 408.25x | 408.25x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
